Ur Advanced Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 12.00 Cr
as on 18-12-2024
- Paid Up Capital ₹ 1.17 Cr
as on 18-12-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 314.23%
(FY 2023)
- Profit 37.37%
(FY 2023)
- Ebitda 65.12%
(FY 2023)
- Net Worth
- Total Assets 92.53%
(FY 2023)
About Ur Advanced Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 12.00 Cr and a paid-up capital of Rs 1.17 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bhanu Kommineni, Jangamreddy Reddy, Aparna Rachamallu, and One other member serve as directors at the Company.
- CIN/LLPIN
U73100TG2020PTC141847
- Company No.
141847
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jul 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ur Advanced Therapeutics?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhanu Kommineni  | Additional Director | 16-Dec-2023 | Current |
| Jangamreddy Reddy | Director | 17-Jul-2020 | Current |
| Aparna Rachamallu | Director | 16-Mar-2023 | Current |
| Sai Anne | Additional Director | 16-Dec-2023 | Current |
Financial Performance and Corporate Structure Insights of Ur Advanced Therapeutics.
Ur Advanced Therapeutics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 314.23% increase. The company also saw a substantial improvement in profitability, with a 37.37% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ur Advanced Therapeutics?
Unlock access to Ur Advanced Therapeutics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Amigos Molecular Solutions Private LimitedActive 5 years 11 monthsAparna Rachamallu is a mutual person
- Ur Revnostics Private LimitedActive 2 years 9 months
Jangamreddy Reddy and Aparna Rachamallu are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ur Advanced Therapeutics?
Ur Advanced Therapeutics has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ur Advanced Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ur Advanced Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
